Please enjoy this edition of the Division 28 newsletter. I have also attached the Division 28 convention program, as well as the programs for Division 25 (Behavior Analysis) and Division 50 (Society of Addiction Psychology).
Below I have also posted an ONDCP press release from yesterday regarding the Synthetic Drug Abuse Prevention Act of 2012 that aims to regulate drugs like the synthetic cannabinoids and bath salts, an issue that was discussed in the Advocacy column in this edition of the newsletter.
Thank you
Kelly
---
Dear Friends:
Yesterday, President Obama signed the Synthetic Drug Abuse Prevention Act of 2012 into law as part of S. 3187, the Food and Drug Administration Safety and Innovation Act. This important piece of legislation provides a critical boost to our nation's efforts to address the threat of synthetic drugs. The legislation bans synthetic compounds commonly found in synthetic marijuana ("K2" or "Spice"), synthetic stimulants ("Bath Salts"), and hallucinogens, by placing them under Schedule I of the Controlled Substances Act.
Although this Federal ban provides a valuable tool in keeping these dangerous substances off the shelves, we would encourage states that have not already done so to incorporate these substances into their state drug schedules to ensure that state law enforcement agencies have full authority to act against these substances. The Drug Enforcement Administration will continue to work with state and local authorities to investigate major distribution networks, but retail and community-level enforcement will continue to occur largely on a state and local level.
We expect that this law will have an impact on illicit sales of these newly scheduled synthetic drugs, at least in the short term. However, Federal and state agencies will have to continue to update the list of banned substances as new synthetic compounds emerge. In addition, some states and localities have also experienced success in using additional health, safety, or agricultural authorities to remove these substances from retail shelves.
Research shows that preventing drug use before it begins is a cost-effective, common-sense approach to promoting safe and healthy communities. In the coming weeks, ONDCP will be unveiling a Synthetic Drug Prevention Toolkit, which we hope will serve as a resource for communities dealing with this issue.
ONDCP is committed to partnering with our state, local, and community partners in addressing this challenge. As always, we are eager to hear from you on what you are seeing in your community and what is working in your own efforts.
Sincerely,
R. Gil Kerlikowske
| Katie Greene Acting Associate Director 202-395-6652 kgreene@ondcp.eop.gov | Quinn Staudt Deputy Associate Director for Stakeholder Outreach 202-395-7453 qstaudt@ondcp.eop.gov | Jacqueline Hackett Deputy Associate Director for Policy 202-395-6675 jhackett@ondcp.eop.gov |
The White House · 1600 Pennsylvania Avenue, NW · Washington DC 20500 · 202-456-1111
--
Kelly Dunn, Ph.D.
Instructor
Johns Hopkins University School of Medicine
5510 Nathan Shock Drive
Baltimore, MD 21224
BPRU Phone: (410) 550-2254
CLH Phone: (410) 550-5370
Fax: (410) 550-0030
WARNING: E-mail sent over the Internet is not secure. Information sent by e-mail may not remain confidential.
DISCLAIMER: This e-mail is intended only for the individual to whom it is addressed. It may be used only in accordance with applicable laws. If you received this e-mail by mistake, notify the sender and destroy the e-mail
_____________________div28announce____________________________
A Division 28 announcement-only list twitter: @apadiv28 join our network
No comments:
Post a Comment